Ablation for oligometastatic colorectal carcinoma in extrahepatic, extrapulmonary sites

Int J Hyperthermia. 2022;39(1):633-638. doi: 10.1080/02656736.2021.1952318.ABSTRACTTreatment of metastatic colorectal carcinoma has evolved in the era of increasingly effective systemic therapies. Increasing survival rates provide opportunities for repeated focal therapies to be directed at limited metastatic disease. Surgical resection and other ablative therapies to eliminate oligometastases in the most common sites, namely liver and lung, have been proven to prolong survival. As such, patients develop additional sites of metastasis in the course of their disease, including adrenal, peritoneal, nodal, and skeletal metastases. Data supporting aggressive focal therapy for extrahepatic, extrapulmonary metastases are limited. This manuscript summarizes findings of surgical studies of cytoreduction in these patients, describes limited data from ablation case series that include these metastases, and presents a rationale for further investigation of thermal ablation within this patient population.PMID:35465801 | DOI:10.1080/02656736.2021.1952318
Source: International Journal of Hyperthermia - Category: Internal Medicine Authors: Source Type: research